| Company Name: |
Suzhou Meishi Biotechnology Co., Ltd.
|
| Tel: |
1173954148q |
| Email: |
meishipharma@126.com |
| Products Intro: |
Product Name:333742-48-6
CAS:333742-48-6
Purity:99% HPLC Package:1G;5G;10G;100G;1KG;
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:AZD8309
CAS:333742-48-6
Purity:99% Package:1mg;5mg;10mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:AZD8309
CAS:333742-48-6
Purity:99.67% Package:1mg/RMB 1320;5mg/RMB 3230;10mg/RMB 4630
|
AZD-8309
(AZD8309) manufacturers
- AZD8309
-
- $129.00 / 1mg
-
2025-11-10
- CAS:333742-48-6
- Min. Order:
- Purity: 99.67%
- Supply Ability: 10g
|
| | AZD-8309
(AZD8309) Basic information |
| Product Name: | AZD-8309
(AZD8309) | | Synonyms: | AZD-8309
(AZD8309);AZD-8309;Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- | | CAS: | 333742-48-6 | | MF: | C15H14F2N4O2S2 | | MW: | 384.42 | | EINECS: | | | Product Categories: | | | Mol File: | 333742-48-6.mol |  |
| | AZD-8309
(AZD8309) Chemical Properties |
| density | 1.56±0.1 g/cm3(Predicted) | | pka | 6.85±0.20(Predicted) | | form | Solid | | color | White to off-white |
| | AZD-8309
(AZD8309) Usage And Synthesis |
| Description | AZD8309 is an oral CXCR2 antagonist. | | Uses | AZD8309 is an orally active antagonist of CXCR2. AZD8309 has the ability to regulate the transmigration of neutrophils. AZD8309 can be used in the study of inflammatory diseases[1]. | | in vivo | AZD8309 (50 mg/kg; p.o.; twice daily) reduces neutrophil migration and pancreatic protease activation in experimental pancreatitis in mice[1]. | Animal Model: | Male C57BL6 mice (25-30 g) with experimental pancreatitis[1] | | Dosage: | 50 mg/kg | | Administration: | Oral gavage; twice daily starting 3 h prior to pancreatitis induction | | Result: | Significantly reduced MPO in the pancreas and lungs (8 h & 24 h) and reduced intrapancreatic trypsin and elastase activity (8 h) in caerulein-pancreatitis.
Reduced serum cytokine levels as well as histopathological damage. |
| | IC 50 | CXCR2: 4 nM (IC50) | | References | [1] Malla SR, et al. Effect of oral administration of AZD8309, a CXCR2 antagonist, on the severity of experimental pancreatitis. Pancreatology. 2016 Sep-Oct;16(5):761-9. DOI:10.1016/j.pan.2016.07.005
[2] Walters I, Austin C, Austin R, et al. Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg Med Chem Lett. 2008;18(2):798-803. DOI:10.1016/j.bmcl.2007.11.039 |
| | AZD-8309
(AZD8309) Preparation Products And Raw materials |
|